• Explore /
  • Poster
  • / Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors.

Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors.

Abstract Poster

Authors

null

Su Jin Lee

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

Su Jin Lee , Jun Soo Ham , Hee Kyung Kim , Seonggyu Byeon , Seon Young Lee , Weon Sup Lee , Jin San Yoo , Jong Mu Sun , Jeeyun Lee , Se Hoon Park , Joon Oh Park , Myung-Ju Ahn , Ho Yeong Lim , Won Ki Kang , Young Suk Park

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics and Translational Research

Sub Track

Angiogenesis

Clinical Trial Registration Number

NCT01660360

Citation

J Clin Oncol 33, 2015 (suppl; abstr 2522)

DOI

10.1200/jco.2015.33.15_suppl.2522

Abstract #

2522

Poster Bd #

238

Abstract Disclosures

Similar Posters

First Author: T.R. Jeffry Evans

First Author: Dongmei Ji

First Author: Sara Michele Federico

First Author: Meredith K. Chuk